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Abstract
Biomedical synthetic biology is an emerging field in which cells are engineered at the genetic 
level to carry out novel functions with relevance to biomedical and industrial applications. This 
approach promises new treatments, imaging tools and diagnostics for diseases ranging from 
gastrointestinal inflammatory syndromes to cancer, diabetes and neurodegeneration. As these 
cellular technologies undergo pre-clinical and clinical development, it is becoming essential to 
monitor their location and function in vivo, necessitating appropriate molecular imaging strategies, 
and therefore we have created an Interest Group within the World Molecular Imaging Society 
focusing on synthetic biology and reporter gene technologies. Here, we highlight recent advances 
in biomedical synthetic biology, including bacterial therapy, immunotherapy and regenerative 
medicine. We then discuss emerging molecular imaging approaches to facilitate in vivo 
applications, focusing on reporter genes for noninvasive modalities such as magnetic resonance, 
ultrasound, photoacoustic imaging, bioluminescence and radionuclear imaging. Because reporter 
genes can be incorporated directly into engineered genetic circuits, they are particularly well 
suited to imaging synthetic biological constructs, and developing them provides opportunities for 
creative molecular and genetic engineering.
MAIN TEXT
Role of imaging in biomedical synthetic biology
Synthetic biology is defined by the development of modified genetic elements, circuits and 
cells to perform new functions that are not part of their normal functional repertoire. Since 
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its initial development starting around 2000, this discipline has impacted diverse fields 
ranging from industrial chemical synthesis to human health1. Advances in synthetic biology 
are accelerating in part due to the exponentially decreasing costs of DNA sequencing, 
synthesis and assembly2, providing a rich catalog of natural genetic elements to use in 
engineered constructs and enabling rapid and inexpensive assembly and testing of genetic 
circuits. The potential of synthetic biology to make an impact in biomedicine3, 4 is 
exemplified by recent developments in cellular diagnostics, therapeutics and genome editing, 
and imaging has been critical in the development and use of these now tools. In principle, 
cells are capable of more sophisticated functionality than molecular or nanoparticle-based 
therapeutic platforms. Cells can migrate, proliferate, detect signals in their environment, 
perform logic operations and produce outputs such as the secretion or display of 
biomolecules, targeted cell killing and suicide5. Similarly, they can carry indicator lights, 
molecular tags or molecular antennae for sensing and imaging. These capabilities have led, 
for example, to the development of genetically programmed microbial cells for 
gastrointestinal and tumor-targeted therapies and diagnostics, engineered immune cells for 
cancer immunotherapy, and other modified cell types for regenerative medicine. In addition 
to cellular therapeutics, gene therapy and genome editing – designed to modify the DNA of 
endogenous cells – are also rapidly emerging as a viable approach to treating a wide range of 
diseases. As discussed below, each of these synthetic biological systems is designed to 
operate at specific anatomical locations in vivo, making it important to monitor its 
distribution and function with molecular imaging technology (Figure 1).
Synthetic biology was first developed in prokaryotes, which provided a convenient platform 
for genetic engineering and industrial applications. In parallel, studies of the mammalian 
microbiome uncovered important roles for bacteria in health and disease, including 
infection, immunity, nervous system function and metabolic homeostasis6–10. The 
convergence of these research areas in now enabling the development of engineered 
microbial therapeutics and diagnostics. These approaches take advantage of bacterial 
species’ natural abilities to occupy certain biological niches, such as stretches of the GI tract 
or hypoxic regions of tumors, sense their environment and release therapies such as 
cytolysins and cytokines, or diagnostic indicators such as β-galactosidase11–16. Logic gates, 
genetic memory devices and kill switches further broaden the capabilities of these 
bacteria17.
In eukaryotic synthetic biology18, immunotherapy has recently emerged as a new class of 
cancer therapy with promising results in hematological malignancies and some solid 
tumors19, 20. This approach takes advantage of immune cells’ ability to eliminate tumors 
based on the recognition of tumor-specific antigens. Cellular immunotherapy works by 
genetically modifying patient T-cells to express novel, engineered receptors for tumor 
antigen recognition and re-introducing them into the body19. In addition to engineered 
receptors, these cells can be designed with cellular logic (e.g., AND gates requiring two 
tumor-specific signals for activation)21 and self-inactivating safety mechanisms22.
Another area of cellular therapy benefiting from synthetic biology is regenerative medicine, 
which offers hope for patients by introducing progenitor cells in situ to induce tissue repair 
and reverse deficits in conditions including diabetes, heart failure and neurodegeneration. 
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Treatment with stem cells is a powerful approach on three levels: (i) stem cells secrete 
cytokines and protective factors that provide trophic support, prevent cell death, and help in 
recovery of the tissue; (ii) stem cells can be used as a vehicle for continuous delivery of 
therapeutic agents locally; (iii) stem cells can differentiate and integrate into a tissue, 
replacing the function of diseased cells. Synthetic biology circuits can be used as switches 
for reprograming of cells, either to push the cells in the direction of pluripotency or in the 
reverse direction toward differentiation into a specific type of cells. For example, by 
synthetically activating the Yamanaka factors23, generation of induced pluripotent stem cells 
(iPSCs) can be achieved3. This fit the model described in figure 2b of an “off”/”on” function 
by activating specific transcription factor under very specific conditions. Additionally, 
communities of cells that associate with each other to form tissues can be generated using 
engineered receptors and ligands24, and indicator switches can be built into cells that reveal 
their proximity to one another through imaging25. Another direction is the construction of 
cellular feedback circuits or oscillators that can allow cyclic production of cytokines, 
metabolites, neurotropic factors or drugs that is built into the stem cells and use the stem 
cells as a delivery vehicle. Examples of this approach include rewiring of optogenetics 
controlled blood glucose levels26 and control of blood levels of uric acid associated with 
gout27.
A major challenge in applying engineered microbial, immune and regenerative cell therapies 
is that the fate of the injected or transplanted cells is largely unknown. After introduction 
into the body, the cells may or may not survive, reach their anatomical target, proliferate, 
differentiate or otherwise carry out their intended function. These factors will profoundly 
influence long-term patient outcomes. While the molecular imaging field has devoted 
considerable attention to in vivo imaging and tracking of cells, it has mostly done so with 
synthetic labels, which are difficult to connect to long-term viability and function, and 
become diluted through proliferation. However, the integration of molecular imaging in to 
the field of synthetic biology is increasing for the purpose of assessing locales and functions 
of cells in vivo; similarly the use of synthetic biology to create novel imaging tools is also 
advancing at a dramatic rate. Therefore, we have created an interest group within the World 
Molecular Imaging Society (WMIS) called Synthetic Biology and Reporter Gene (SyBRG) 
to address this rapidly advancing intersection of technologies. Here we review this 
technological interface and point to future directions where the combination of tools 
addresses critical unmet needs in biomedicine.
In addition to enabling new cellular therapies, synthetic biology provides new methods to 
alter the genetic contents of existing cells. Breakthroughs in genome editing such as zinc-
finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and 
clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas systems28, have 
reinvigorated the field of gene therapy by making it possible to fix errant genes and precisely 
introduce synthetic circuits into mammalian cells. Using a single vector, a specific gene can 
be targeted and suppressed with an efficiency and accuracy that were not possible 
previously29. Like cell therapy, in vivo gene therapy and genome editing are usually targeted 
to specific cell types and anatomical locations, making it critical to image their fate in the 
body. By designing appropriate molecular imaging tools it may be possible to fine tune and 
help translate many of these technologies to the clinic.
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Development of reporter genes for noninvasive imaging of engineered cells and genetic 
vectors
A natural imaging approach for synthetic biology makes use of reporter genes, whose 
products are proteins that produce signals detectable with imaging modalities, wherein the 
gene is either fused to the gene of interest or, most commonly, cloned under its cognate 
promoter (Figure 2). The main applications for these reporters include: (i) monitoring gene 
expression levels; (ii) investigating dynamic molecular signaling; (iii) studying cellular 
interactions and (iv) tracking cells in normal and abnormal development or cellular therapy. 
The first reporter genes (Figure 3) were designed to catalyze chemical reactions that produce 
a light-absorbing pigment, and later to generate photons following fluorescent30, 31 or 
chemiluminescent excitation32–35. This pioneering work created for the first time a 
connection between molecular biology and imaging. In the early nineties, this field was 
expended to nuclear imaging36, 37 and MRI38.
MRI reporters have been developed to use a variety of mechanisms afforded by spin physics. 
Pioneering examples include enzymes that alter the relaxivity of gadolinium chelates39, 
human iron storage and transport genes such as ferritin40, 41 and transferrin42, and natural 
and engineered proteins with large numbers of chemically labile protons for chemical 
exchange saturation transfer (CEST) imaging43–48. Recent developments have also included 
reporter genes causing accumulation of MRI-detectable compounds49, proteins interacting 
with hyperpolarized molecules50, 51, channels that alter the diffusion of water across cell 
membranes52, 53 and vasodilators altering hemodynamic signals54. Several of these reporter 
genes are covered in detail in previous review articles55–57. Nuclear imaging reporter genes, 
some of which have already been tested in the clinic58, typically lead to cellular 
accumulation of radiolabeled nucleotides for imaging with positron emission tomography or 
single photon emission computed tomography59.
As a complement to existing reporter gene modalities, ultrasound is inexpensive, non-
ionizing, portable, and capable of imaging deep tissues60 with sub-millisecond temporal 
resolution and a spatial resolution scalable with penetration depth—see review in this issue 
on Ultrasound Molecular Imaging and Drug Delivery. For example, in small animal 
imaging, the spatial resolution of high-frequency ultrasound (> 15 MHz) is routinely below 
100 μm61, 62 and can approach the single-micron level with recently developed super-
resolution techniques63. Although no ultrasound reporter genes current exist, a unique class 
of biomolecules called gas vesicles – gas-filled protein nanostructures from buoyant 
photosynthetic microbes – was recently found to produce ultrasound contrast64. Efforts are 
now underway to engineer these molecules at the genetic level65 and express them 
heterologously as reporter genes. In addition, photoacoustic imaging, which combines 
diffuse optical excitation with acoustic readout for in vivo imaging applications66, 67, has 
engendered the development of optically absorbing molecules as reporter genes68–70.
Challenges and opportunities
With the emergence of the synthetic biology as a field, it is possible to engineer 
microorganisms and mammalian cells and use them as diagnostic tools. Harnessing the 
power of molecular imaging can be a game changer for synthetic biology by improving the 
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ability to look closely into processes in live organisms. On the other hand, we can use 
synthetic biology to manufacture more robust imaging probes. For example, one of the 
challenges of the traditional molecular imaging reporter genes is that the reporters are not 
switchable i.e., the reporters are constantly activated. Using synthetic biology tools this 
hurdle can be overcome. Building a switch can ensure that the reporter can provide a signal 
only at the right place and the right time. Circuit designs such as oscillators can provide a 
unique temporal aspect to reporter gene signals, helping distinguish them from background. 
Another emerging frontier of reporter gene engineering relates to genetically encoded 
sensors of dynamic cellular signals such as calcium, phosphorylation and neurotransmission. 
Such sensors based on fluorescent proteins are already widely used in optically accessible 
preparations71, and recent efforts have focused on developing such sensors for MRI72 and 
photoacoustic imaging.
Another potential direction is to augment the visualization capabilities of molecular imaging 
with the ability to intervene non-invasively in the function of cells in the target tissue. For 
example if we are already delivering into the tissue energy in the form of, light, ultrasound 
or electromagnetic fields, we could also use it, either directly or via conversion to heat73–75, 
to activate intracellular molecules, proteins or cells.
In summary, as synthetic biology moves toward in vivo biomedical applications, it is 
becoming critical to monitor the functionality of genetically engineered devices in intact 
model organisms and patients. Molecular imaging technologies such as reporter genes are 
primed to address this challenge, and we feature these advances at the annual meeting of the 
WMIS and endeavor to advance this field though fostering interaction and collaborations 
between scientists using imaging to reveal spatiotemporal functions of engineered cells, and 
those using synthetic biology to advance imaging tools for biomedical applications.
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Figure 1. Emerging approached in biomedical synthetic biology and molecular imaging
(a) Illustration of genetically reprogrammed stem cell differentiating into a neuron following 
implantation into the brain. (b) Illustration of microbial cell in the gastrointestinal tract 
engineered to release cytokines after a logical AND computation established the presence of 
hypoxic and inflammatory inputs. (c) T-cell engineered with a chimeric antigen receptor to 
recognize a specific tumor antigen. (d) MRI image of cells implanted into a mouse brain 
using CEST imaging of a lysine-rich protein (used with permission from Ref X). (e) Cross-
sectional ultrasound image of a mouse torso showing bladder and colon. (f) PET image of T-
cells heterologously expressing a T-cell receptor and a reporter gene causing accumulation 
of a PET tracer, following in vivo activation of the cells.
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Figure 2. the importance of reporter genes for in vivo imaging of synthetic biology
(a) There are several “bioparts” and biological circuits that can be used for activation of 
reporter genes. For example, light activated channels (optogenetics) or other membrane 
channels and receptors can that activate the transcription factors (Tf) that binds to specific 
gene promoters and consequently will transcribe reporter genes. This is useful for imaging 
of “toggle switches” that will result in “on/off” pattern (b) and are important for example to 
report on (stem) cell differentiation or cell fate. Co-expression of the reporter with repressors 
(Rep) can results in creating “oscillators” that are important for controlled release of 
metabolites, cytokines, drugs and neurotropic factors (c).
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Reporter genes, Illustration of the operating principles of (a) reporter genes for (b) optical 
imaging, (c) radionuclear imaging, (d) MRI and (e) ultrasound. Optical reporter genes 
convert optical excitation or chemiluminescent substrate bond energy into photons. 
Radionuclear reporter genes concentrate radioactive substrates in cells, e.g. by 
phosphorylating them. MRI reporters are detected via a variety of interactions with aqueous 
protons or other nuclei such as hyperpolarized xenon. Ultrasound reporters could be based 
on proteins capable of scattering sound waves.
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